FDG-PET/CT for Simulation and Radiation Treatment Planning of Early Breast Cancer
Study Details
Study Description
Brief Summary
The purpose of the study is:
-
to assess the potential benefits of 18F-[FDG] PET/CT and PET/MRI for operable breast cancer in order to define the size and location of the primary tumor, as well as axillary, supraclavicular and internal mammary lymph nodes.
-
to apply the imaging results to the simulation and the radiation treatment planning and partial breast for 3-D radiation treatment and partial breast irradiation with intensity modulated radiation treatment (IMRT).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Pre-operative FDG PET/CT, and in option PET/IRM, are intended for women with histologically confirmed operable clinically node-negative breast cancer, in whom breast conserving and post-operative radiotherapy are planned.
Study Design
Outcome Measures
Primary Outcome Measures
- Drawing of target volumes [Up to 12 weeks after surgery]
Compare the drawing of target volumes using the PET/CT, PET/IRM information, or without these imaging informations.
Secondary Outcome Measures
- Correlate the FDG PET/CT PET/IRM with surgical pathology findings [Up to 12 weeks after surgery]
Compare the pre-operative imaging information with histopathological description of the resected primary tumor, and with the extent of lymph node involvement.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed breast carcinoma
-
Clinical stage T1-2 N0 M0
-
Age > 18 years
-
Signed informed consent
Exclusion Criteria:
-
WHO performance index 3
-
Premenopausal women without contraception
-
Gestation
-
Lactating
-
Prior surgery or radiotherapy on the same breast
-
Unable to understand study participation
-
Bilateral breast cancer
-
Prior CT thorax-abdomen and breast MRI within 4 months of interview
-
Presence of electromechanical implant and/or body ferromagnetic material
-
Previous history of renal insufficiency requiring dialysis and/or hospitalisation
-
Ureum and/or creatinine within 2 weeks of interview above lab's reference limits
-
History of contrast allergy
-
Hyperthyroidy
-
Claustrophobia.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Radiation oncology, Geneva University Hospitals | Geneva | Switzerland | 1205 |
Sponsors and Collaborators
- University Hospital, Geneva
Investigators
- Principal Investigator: Vincent Vinh-Hung, MD, PhD, Radiation Oncology, Geneva University Hospitals
Study Documents (Full-Text)
None provided.More Information
Publications
- Bral S, Vinh-Hung V, Everaert H, De Coninck P, Storme G. The use of molecular imaging to evaluate radiation fields in the adjuvant setting of breast cancer: a feasibility study. Strahlenther Onkol. 2008 Feb;184(2):100-4. doi: 10.1007/s00066-008-1769-7.
- Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, Verfaillie G, Fontaine C, Vees H, Ratib O, Vlastos G, De Ridder M. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging. 2012 Oct;39(10):1618-27. Epub 2012 Jul 10.
- HUG 07-153